US-based immuno-oncology company Heat Biologics intends to raise funds through an underwritten public offering of shares of its common stock, with Aegis Capital as the book-running manager.
The proceeds are intended to fund the clinical and pre-clinical trials of the company, as well as its subsidiaries, and for working capital and general corporate purposes. Part of the funds will also be used for other purposes such as acquiring, licensing or investing in complementary businesses, technologies or intellectual property.
US-based biopharmaceutical company Bellicum Pharmaceuticals has announced an underwritten public offering of shares to raise funds for its ongoing and planned clinical trials on a number of products.
The offering includes five million shares of the company’s common stock, while underwriters will have a 30-day option to purchase up to an additional 750,000 shares to cover over-allotments, if any.
US-based biopharmaceutical company SutroVax has completed a series B financing round led by Frazier Healthcare Partners and Pivotal bioVenture Partners.
The company has raised $64m through the round, which will be invested in advancing the company’s pneumococcal conjugate vaccine and accelerating its antigen discovery and early stage development efforts in other disease areas.
Biotechnology company Regenxbio has announced the pricing for its proposed underwritten public offering of shares.
The offering includes 3.7 million shares of the company’s common stock and is priced at $20.5 a share and will raise gross proceeds of $75.85m for the company.
Underwriters are granted a 30-day option to purchase up to an additional 555,000 shares at the same price.
The offering is expected to be closed on 27 March.
Minerva Neurosciences has raised $9.4m in gross proceeds from the private placement of shares of its common stock.
The placement included 1.6 million shares priced at $5.772 a share.
Based in the US, Minerva is a clinical-stage biopharmaceutical company.
UK-based drug discovery company Pulmocide has completed a series B venture financing round led by SR One.
The company has raised $30.4m through the financing round, which is intended to support the company’s early clinical development efforts.